Diabetes Awareness Month
The Amniox Advantage: Addressing the Challenge of Chronic Wounds
The Amniox comprehensive family of umbilical cord and amniotic membrane products harnesses the unique power of human birth tissue to help expedite regenerative healing across a wide range of specialties as the adjunct for acute and chronic wound applications by helping to:
- Facilitate wound healing
- Manage discomfort
- Manage adhesions
- Expedite functional recovery while reducing the cost of care 1-4
Built on a Foundation of Relentless Clinical Pursuit, Discovery, and Cost-Effective Solutions
The Solution is in Our Platform Technology — HC-HA/PTX3
Our pioneering scientists have focused on understanding the properties of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in healing in the human fetal environment.5-9
This complex may orchestrate anti-inflammatory, anti-scarring and growth-promoting biological effects that may expedite functional recovery as demonstrated on the ocular space.5,10
Our CRYOTEK® cryopreservation process has been shown to preserve the structural integrity of the HC-HA/PTX3 complex significantly better than heat dehydration—delivering the benefit of the natural tissue to the wound.11,12
The Clinical and Economic Challenges of Diverse Wound Conditions and Infections
Industry experts recognize the increasing burden of non-healing wound infections.
14.5% of Medicare beneficiaries in 2014 (8.2 million patients) were diagnosed with at least one type of wound or wound-related infection. Listed by prevalence:
- Surgical wound infections, the largest category, at 4%
- Diabetic wound infections 3.4%
- Non-healing surgical wounds 3%13
This cost could range from $31.7 billion to $96.8 billion including wounds as a secondary diagnosis.13
NEOX CORD 1K: A treatment option specifically targeted to complex DFU Wagner 3-4 wounds
- NEOX CORD 1K can help expedite healing in patients with Wagner 3-4 ulcers with an average of 1.5 applications2,3
- NEOX CORD 1K is suitable for complex wounds with exposure of muscle, tendon and bone where many conventional advanced skin substitutes and skin grafts are contraindicated2,3
- Our phase II prospective Biologics License Application (BLA) trial reinforces the clinical outcomes1
- Our product pipeline is focused on patients most at risk for amputation
- Our technology can help reduce the cost of care by helping to expedite functional recovery for the patient2,4
Neox Umbilical Cord Allografts (UC) vs. Amniotic Membrane (AM)
Valuable Resources
Advanced Therapy Treatments in Lower Extremity Wound Healing
Advanced wound therapy treatments are experiencing a rapid adoption rate as an adjunct to the standard of care. In this webinar, Dr. Alan Block provided a contemporary overview of Amniotic Membrane and Umbilical Cord transplantation and shared challenging cases specific to a variety of lower extremity applications where expedited wound healing and functional recovery are a concern.
You can watch Dr. Block’s webinar in its entirety by signing up for the Physician Portal and accessing archived webinars on-demand by clicking the button below.